[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594837":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":231,"collaborators":25,"id":233,"slug":234,"hasResults":235,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":25,"eligibilityCriteria":239,"healthyVolunteers":235,"sex":240,"minAge":241,"maxAge":25,"enrollmentInfo":242,"targetDuration":25,"studyType":245,"phases":246,"briefSummary":248,"conditions":249,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},{"fullName":5,"class":6},"GigaGen, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Single Ascending Dose (SAD)","EXPERIMENTAL","Participants will receive a single IV infusion of either GIGA-2339 or placebo in ascending doses on Day 1.",[13,14],"Drug: GIGA-2339","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 2: Multiple Ascending Dose (MAD)","Participants will receive multiple IV infusions of either GIGA-2339 or placebo, once every 4 weeks, at a dose determined in Part 1.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","GIGA-2339","Administered by intravenous infusion",[9,16],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Placebo",[9,16],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Enrikas Vainorius, MD","CONTACT","+1 919-316-6396","giga2339study@grifols.com",[36,52,63,73,83,92,104,115,126,137,148,158,169,183,194,205,215,221],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Grifols Investigative site","RECRUITING","Chandler","Arizona","85225","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-111.84125,33.30616,{"lat":48,"lon":47},[51],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":53,"state":54,"zip":55,"country":42,"countryCode":43,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Huntington Beach","California","92647",{"type":45,"coordinates":57},[58,59],-117.99923,33.6603,{"lat":59,"lon":58},[62],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":64,"state":54,"zip":65,"country":42,"countryCode":43,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Lake Forest","92630",{"type":45,"coordinates":67},[68,69],-117.68922,33.64697,{"lat":69,"lon":68},[72],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":74,"state":54,"zip":75,"country":42,"countryCode":43,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Long Beach","90805",{"type":45,"coordinates":77},[78,79],-118.18923,33.76696,{"lat":79,"lon":78},[82],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":84,"city":85,"state":54,"zip":86,"country":42,"countryCode":43,"cosmosGeoPoint":87,"geoPoint":91,"contacts":25},"SUSPENDED","Oakland","94605",{"type":45,"coordinates":88},[89,90],-122.2708,37.80437,{"lat":90,"lon":89},{"facility":93,"status":38,"city":94,"state":95,"zip":96,"country":42,"countryCode":43,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Grifols Investigative Site","Peachtree Corners","Georgia","30071",{"type":45,"coordinates":98},[99,100],-84.22159,33.9701,{"lat":100,"lon":99},[103],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":93,"status":38,"city":105,"state":106,"zip":107,"country":42,"countryCode":43,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Iowa City","Iowa","52242",{"type":45,"coordinates":109},[110,111],-91.53017,41.66113,{"lat":111,"lon":110},[114],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":93,"status":38,"city":116,"state":117,"zip":118,"country":42,"countryCode":43,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Lenexa","Kansas","66219",{"type":45,"coordinates":120},[121,122],-94.73357,38.95362,{"lat":122,"lon":121},[125],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":127,"state":128,"zip":129,"country":42,"countryCode":43,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Baltimore","Maryland","21287",{"type":45,"coordinates":131},[132,133],-76.61219,39.29038,{"lat":133,"lon":132},[136],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":138,"state":139,"zip":140,"country":42,"countryCode":43,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"San Antonio","Texas","78215",{"type":45,"coordinates":142},[143,144],-98.49363,29.42412,{"lat":144,"lon":143},[147],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":149,"state":139,"zip":150,"country":42,"countryCode":43,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Webster","77598",{"type":45,"coordinates":152},[153,154],-95.11826,29.53773,{"lat":154,"lon":153},[157],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":159,"state":160,"zip":161,"country":42,"countryCode":43,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Richmond","Virginia","23284",{"type":45,"coordinates":163},[164,165],-77.46026,37.55376,{"lat":165,"lon":164},[168],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":170,"status":38,"city":171,"state":172,"zip":173,"country":174,"countryCode":175,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Grifols Investigate Site","Concord","New South Wales","2139","Australia","AU",{"type":45,"coordinates":177},[178,179],151.10381,-33.84722,{"lat":179,"lon":178},[182],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":184,"state":185,"zip":186,"country":174,"countryCode":175,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Fortitude Valley","Queensland","4006",{"type":45,"coordinates":188},[189,190],153.03178,-27.45706,{"lat":190,"lon":189},[193],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":195,"state":196,"zip":25,"country":195,"countryCode":197,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Hong Kong","Hong Kong Island","HK",{"type":45,"coordinates":199},[200,201],114.17469,22.27832,{"lat":201,"lon":200},[204],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":206,"state":207,"zip":25,"country":195,"countryCode":197,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"Shatin","New Territories",{"type":45,"coordinates":209},[210,211],114.18333,22.38333,{"lat":211,"lon":210},[214],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":216,"state":217,"zip":25,"country":218,"countryCode":25,"cosmosGeoPoint":25,"geoPoint":25,"contacts":219},"Seogu","Busan","South Korea",[220],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"facility":37,"status":38,"city":222,"state":223,"zip":25,"country":218,"countryCode":25,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Songpa-dong","Seoul",{"type":45,"coordinates":225},[226,227],127.12222,37.50139,{"lat":227,"lon":226},[230],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"type":232,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100594837","phase-1-a-study-to-assess-the-safety-tolerability-and-pharmacokinetics-of-giga-2339-in-participants-with-chronic-hepatitis-b-virus-infection-100594837",false,"NCT07024641","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection","Key Inclusion Criteria:\n\n* Hepatitis B envelope antigen (HBeAg) negative chronic HBV infection for ≥ 6 months, defined as presence of Hepatitis B surface antigen (HBsAg) in serum for ≥ 6 months.\n* Serum HBsAg concentration between ≥ 100 international units per milliliter (IU\u002FmL) and 2000 IU\u002FmL at screening.\n* Currently on stable dose of nucleot(s)ide analogues (NAs) (≥ 6 months) and expected to continue while participating in the study, or are not received NAs.\n* Have serum HBV deoxyribonucleic acid (DNA) concentration ≤ 50 IU\u002FmL at screening (for those who are on NAs); or have serum HBV DNA concentration ≤ 2000 IU\u002FmL at screening (for those who are NOT on NAs).\n* Male participants must refrain from donating spermatozoa and agree to use highly effective contraception.\n* Female participants must not be pregnant, or breastfeeding; either should not be a woman of childbearing potential (WOCBP) or if WOCBP should use highly effective contraceptive methods.\n\nKey Exclusion Criteria:\n\n* Positive for co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and\u002For hepatitis D virus (HDV) at screening.\n* Participants that weigh less than 50 kilograms (kg) and\u002For have a body mass index (BMI) less than 18.5.\n* History of documented liver cirrhosis at screening. Patients under liver cirrhosis evaluation at screening will not be eligible until cirrhosis is ruled out.\n* Liver stiffness \\> 8 kilopascal (kPa) at screening.\n* History of chronic liver disease from another cause, immune complex disease, or autoimmune diseases that in the opinion of the investigator would preclude participation.\n* Family history of hepatocellular carcinoma (HCC).\n* Alpha fetoprotein \\> 20 nanograms per milliliter (ng\u002FmL).\n* Presence of a liver imaging reporting and data system (LI-RADS) 4 or 5 liver lesion on imaging 12 months prior to Screening OR, LI-RADS-US findings of US-3 grade on imaging 12 months prior to Screening, OR LIRADS-US grade 3 done prior to the D1 infusion visit, if prior LI-RADS or LI-RADS-US results are not available at Screening.\n* History of hematopoietic stem cell transplant or solid organ transplant.\n* Receipt of anti-HBV monoclonal antibody (mAb)\u002FpAb therapy of any kind in the past (including hepatitis B immunoglobulin \\[HBIG\\]).\n* History of cardiovascular disease (e.g., coronary artery disease, cardiomyopathy, congestive heart failure, family history of congenital long QT syndrome). Stable hypertension is allowed.\n* Malignancy diagnosed and\u002For treated within 5 years prior to Screening, and\u002For with ongoing treatment for malignancy, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent.\n* Participants requiring anti-coagulation therapies (for example warfarin, Factor Xa inhibitors, or anti-platelet agents like clopidogrel).\n* Male participants with a corrected QT interval using Fridericia's formula (QTcF) \\> 450 milliseconds (msec) and female participants with QTcF \\> 470 msec on ECG recorded at screening. if the participant has evidence of an intraventricular conduction delay, defined as QRS interval greater than 110 msec, a QTcF is \\> 500 msec for both males and females will be excluded.\n* Known hypersensitivity to any GIGA-2339 excipients or any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (nonactive hay fever is acceptable), or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates participation.\n* Received or will receive live-attenuated virus vaccinations such as measles, mumps, rubella or varicella within 4 weeks before and up to three months after administration of investigational product (IP).","ALL","18 Years",{"count":243,"type":244},48,"ESTIMATED","INTERVENTIONAL",[247],"PHASE1","The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.",[250],"Hepatitis B Virus Infection","2026-06-23",{"date":253,"type":254},"2026-06-25","ACTUAL",{"date":256,"type":254},"2024-11-13",{"date":258,"type":244},"2028-11",{"name":5,"class":6},18]